Discussion:
Unaffordable Cancer Medicines
(too old to reply)
Goanet News Service
2010-11-18 16:08:35 UTC
Permalink
Unaffordable Cancer Medicines

Drugs for treatment of cancer patients are not covered in the list of
controlled drugs under Drugs (Price Control) order, 1995 (DPCO, 1995).
The prices of anti-cancer drugs are, therefore, fixed by the
manufacturers themselves taking into account various factors such as the
cost of bulk drugs used in formulations, cost of excipients, cost of R&D
etc. As per available information, it has been observed that prices of
medicines for treatment of cancer are high particularly in the context
of long duration of treatment of cancer patients. Presently there are 74
bulk drugs included in the First Schedule of DPCO, 95, on the basis of
the criteria given in the Modifications in Drug Policy, 1986. The prices
of these 74 bulk drugs, and the formulations containing any of these
Scheduled drugs are controlled by the Government/NPPA as per the
provisions of DPCO, 1995.

Specified life saving drugs including anti-cancer, anti-AIDS drugs and
bulk drugs of their manufacturer have been exempted from Custom/Excise
Duty. Further, certain states have also exempted life savings drugs from
VAT. In the recent past, the Government has reduced the rate of excise
duty twice on Drugs & Pharmaceuticals from 16% to 8% vide notification
no. 4/2008-CE dated 01.03.2008 and subsequently from 8% to 4% vide
notification no. 58/2008-CE dated 07.12.2008. The reduction in the
excise duty has resulted in reduction in the prices of scheduled drugs
and formulations, the prices of which are fixed by the National
Pharmaceutical Pricing Authority (NPPA) under the provisions of the
Drugs (Prices Control) Order, 1995 (DPCO, 1995). Whenever rates of
excise duty, custom duty etc. are revised, the NPPA issues a
notification quantifying the impact on the prices of scheduled drugs and
formulations fixed by it. In case of medicines out of price control,
i.e. non scheduled drugs/formulations, NPPA also issues advisories to
drug companies to pass on the benefits to the consumers whenever there
is reduction in excise duty etc.

This information was given by the Minister of State for Chemicals and
Fertilizers Shri Srikant Kumar Jena in a written reply in the Lok Sabha
today.

PKM/SB


http://pib.nic.in/newsite/PrintRelease.aspx?relid=67224
Goanet News Service
2010-11-18 16:08:35 UTC
Permalink
Unaffordable Cancer Medicines

Drugs for treatment of cancer patients are not covered in the list of
controlled drugs under Drugs (Price Control) order, 1995 (DPCO, 1995).
The prices of anti-cancer drugs are, therefore, fixed by the
manufacturers themselves taking into account various factors such as the
cost of bulk drugs used in formulations, cost of excipients, cost of R&D
etc. As per available information, it has been observed that prices of
medicines for treatment of cancer are high particularly in the context
of long duration of treatment of cancer patients. Presently there are 74
bulk drugs included in the First Schedule of DPCO, 95, on the basis of
the criteria given in the Modifications in Drug Policy, 1986. The prices
of these 74 bulk drugs, and the formulations containing any of these
Scheduled drugs are controlled by the Government/NPPA as per the
provisions of DPCO, 1995.

Specified life saving drugs including anti-cancer, anti-AIDS drugs and
bulk drugs of their manufacturer have been exempted from Custom/Excise
Duty. Further, certain states have also exempted life savings drugs from
VAT. In the recent past, the Government has reduced the rate of excise
duty twice on Drugs & Pharmaceuticals from 16% to 8% vide notification
no. 4/2008-CE dated 01.03.2008 and subsequently from 8% to 4% vide
notification no. 58/2008-CE dated 07.12.2008. The reduction in the
excise duty has resulted in reduction in the prices of scheduled drugs
and formulations, the prices of which are fixed by the National
Pharmaceutical Pricing Authority (NPPA) under the provisions of the
Drugs (Prices Control) Order, 1995 (DPCO, 1995). Whenever rates of
excise duty, custom duty etc. are revised, the NPPA issues a
notification quantifying the impact on the prices of scheduled drugs and
formulations fixed by it. In case of medicines out of price control,
i.e. non scheduled drugs/formulations, NPPA also issues advisories to
drug companies to pass on the benefits to the consumers whenever there
is reduction in excise duty etc.

This information was given by the Minister of State for Chemicals and
Fertilizers Shri Srikant Kumar Jena in a written reply in the Lok Sabha
today.

PKM/SB


http://pib.nic.in/newsite/PrintRelease.aspx?relid=67224
Goanet News Service
2010-11-18 16:08:35 UTC
Permalink
Unaffordable Cancer Medicines

Drugs for treatment of cancer patients are not covered in the list of
controlled drugs under Drugs (Price Control) order, 1995 (DPCO, 1995).
The prices of anti-cancer drugs are, therefore, fixed by the
manufacturers themselves taking into account various factors such as the
cost of bulk drugs used in formulations, cost of excipients, cost of R&D
etc. As per available information, it has been observed that prices of
medicines for treatment of cancer are high particularly in the context
of long duration of treatment of cancer patients. Presently there are 74
bulk drugs included in the First Schedule of DPCO, 95, on the basis of
the criteria given in the Modifications in Drug Policy, 1986. The prices
of these 74 bulk drugs, and the formulations containing any of these
Scheduled drugs are controlled by the Government/NPPA as per the
provisions of DPCO, 1995.

Specified life saving drugs including anti-cancer, anti-AIDS drugs and
bulk drugs of their manufacturer have been exempted from Custom/Excise
Duty. Further, certain states have also exempted life savings drugs from
VAT. In the recent past, the Government has reduced the rate of excise
duty twice on Drugs & Pharmaceuticals from 16% to 8% vide notification
no. 4/2008-CE dated 01.03.2008 and subsequently from 8% to 4% vide
notification no. 58/2008-CE dated 07.12.2008. The reduction in the
excise duty has resulted in reduction in the prices of scheduled drugs
and formulations, the prices of which are fixed by the National
Pharmaceutical Pricing Authority (NPPA) under the provisions of the
Drugs (Prices Control) Order, 1995 (DPCO, 1995). Whenever rates of
excise duty, custom duty etc. are revised, the NPPA issues a
notification quantifying the impact on the prices of scheduled drugs and
formulations fixed by it. In case of medicines out of price control,
i.e. non scheduled drugs/formulations, NPPA also issues advisories to
drug companies to pass on the benefits to the consumers whenever there
is reduction in excise duty etc.

This information was given by the Minister of State for Chemicals and
Fertilizers Shri Srikant Kumar Jena in a written reply in the Lok Sabha
today.

PKM/SB


http://pib.nic.in/newsite/PrintRelease.aspx?relid=67224
Goanet News Service
2010-11-18 16:08:35 UTC
Permalink
Unaffordable Cancer Medicines

Drugs for treatment of cancer patients are not covered in the list of
controlled drugs under Drugs (Price Control) order, 1995 (DPCO, 1995).
The prices of anti-cancer drugs are, therefore, fixed by the
manufacturers themselves taking into account various factors such as the
cost of bulk drugs used in formulations, cost of excipients, cost of R&D
etc. As per available information, it has been observed that prices of
medicines for treatment of cancer are high particularly in the context
of long duration of treatment of cancer patients. Presently there are 74
bulk drugs included in the First Schedule of DPCO, 95, on the basis of
the criteria given in the Modifications in Drug Policy, 1986. The prices
of these 74 bulk drugs, and the formulations containing any of these
Scheduled drugs are controlled by the Government/NPPA as per the
provisions of DPCO, 1995.

Specified life saving drugs including anti-cancer, anti-AIDS drugs and
bulk drugs of their manufacturer have been exempted from Custom/Excise
Duty. Further, certain states have also exempted life savings drugs from
VAT. In the recent past, the Government has reduced the rate of excise
duty twice on Drugs & Pharmaceuticals from 16% to 8% vide notification
no. 4/2008-CE dated 01.03.2008 and subsequently from 8% to 4% vide
notification no. 58/2008-CE dated 07.12.2008. The reduction in the
excise duty has resulted in reduction in the prices of scheduled drugs
and formulations, the prices of which are fixed by the National
Pharmaceutical Pricing Authority (NPPA) under the provisions of the
Drugs (Prices Control) Order, 1995 (DPCO, 1995). Whenever rates of
excise duty, custom duty etc. are revised, the NPPA issues a
notification quantifying the impact on the prices of scheduled drugs and
formulations fixed by it. In case of medicines out of price control,
i.e. non scheduled drugs/formulations, NPPA also issues advisories to
drug companies to pass on the benefits to the consumers whenever there
is reduction in excise duty etc.

This information was given by the Minister of State for Chemicals and
Fertilizers Shri Srikant Kumar Jena in a written reply in the Lok Sabha
today.

PKM/SB


http://pib.nic.in/newsite/PrintRelease.aspx?relid=67224
Goanet News Service
2010-11-18 16:08:35 UTC
Permalink
Unaffordable Cancer Medicines

Drugs for treatment of cancer patients are not covered in the list of
controlled drugs under Drugs (Price Control) order, 1995 (DPCO, 1995).
The prices of anti-cancer drugs are, therefore, fixed by the
manufacturers themselves taking into account various factors such as the
cost of bulk drugs used in formulations, cost of excipients, cost of R&D
etc. As per available information, it has been observed that prices of
medicines for treatment of cancer are high particularly in the context
of long duration of treatment of cancer patients. Presently there are 74
bulk drugs included in the First Schedule of DPCO, 95, on the basis of
the criteria given in the Modifications in Drug Policy, 1986. The prices
of these 74 bulk drugs, and the formulations containing any of these
Scheduled drugs are controlled by the Government/NPPA as per the
provisions of DPCO, 1995.

Specified life saving drugs including anti-cancer, anti-AIDS drugs and
bulk drugs of their manufacturer have been exempted from Custom/Excise
Duty. Further, certain states have also exempted life savings drugs from
VAT. In the recent past, the Government has reduced the rate of excise
duty twice on Drugs & Pharmaceuticals from 16% to 8% vide notification
no. 4/2008-CE dated 01.03.2008 and subsequently from 8% to 4% vide
notification no. 58/2008-CE dated 07.12.2008. The reduction in the
excise duty has resulted in reduction in the prices of scheduled drugs
and formulations, the prices of which are fixed by the National
Pharmaceutical Pricing Authority (NPPA) under the provisions of the
Drugs (Prices Control) Order, 1995 (DPCO, 1995). Whenever rates of
excise duty, custom duty etc. are revised, the NPPA issues a
notification quantifying the impact on the prices of scheduled drugs and
formulations fixed by it. In case of medicines out of price control,
i.e. non scheduled drugs/formulations, NPPA also issues advisories to
drug companies to pass on the benefits to the consumers whenever there
is reduction in excise duty etc.

This information was given by the Minister of State for Chemicals and
Fertilizers Shri Srikant Kumar Jena in a written reply in the Lok Sabha
today.

PKM/SB


http://pib.nic.in/newsite/PrintRelease.aspx?relid=67224
Goanet News Service
2010-11-18 16:08:35 UTC
Permalink
Unaffordable Cancer Medicines

Drugs for treatment of cancer patients are not covered in the list of
controlled drugs under Drugs (Price Control) order, 1995 (DPCO, 1995).
The prices of anti-cancer drugs are, therefore, fixed by the
manufacturers themselves taking into account various factors such as the
cost of bulk drugs used in formulations, cost of excipients, cost of R&D
etc. As per available information, it has been observed that prices of
medicines for treatment of cancer are high particularly in the context
of long duration of treatment of cancer patients. Presently there are 74
bulk drugs included in the First Schedule of DPCO, 95, on the basis of
the criteria given in the Modifications in Drug Policy, 1986. The prices
of these 74 bulk drugs, and the formulations containing any of these
Scheduled drugs are controlled by the Government/NPPA as per the
provisions of DPCO, 1995.

Specified life saving drugs including anti-cancer, anti-AIDS drugs and
bulk drugs of their manufacturer have been exempted from Custom/Excise
Duty. Further, certain states have also exempted life savings drugs from
VAT. In the recent past, the Government has reduced the rate of excise
duty twice on Drugs & Pharmaceuticals from 16% to 8% vide notification
no. 4/2008-CE dated 01.03.2008 and subsequently from 8% to 4% vide
notification no. 58/2008-CE dated 07.12.2008. The reduction in the
excise duty has resulted in reduction in the prices of scheduled drugs
and formulations, the prices of which are fixed by the National
Pharmaceutical Pricing Authority (NPPA) under the provisions of the
Drugs (Prices Control) Order, 1995 (DPCO, 1995). Whenever rates of
excise duty, custom duty etc. are revised, the NPPA issues a
notification quantifying the impact on the prices of scheduled drugs and
formulations fixed by it. In case of medicines out of price control,
i.e. non scheduled drugs/formulations, NPPA also issues advisories to
drug companies to pass on the benefits to the consumers whenever there
is reduction in excise duty etc.

This information was given by the Minister of State for Chemicals and
Fertilizers Shri Srikant Kumar Jena in a written reply in the Lok Sabha
today.

PKM/SB


http://pib.nic.in/newsite/PrintRelease.aspx?relid=67224

Loading...